Cambridge, UK – 26 October 2021: Cambridge Healthcare Innovations Ltd (CHI), a medical device technology development company, is pleased to announce the appointment of Philip Canner as Chief Executive Officer (CEO) with immediate effect.
Philip has over 15 years’ experience in Life Sciences, Pharma, MedTech, and consultancy, with a proven track record in the development of novel drug-delivery technologies and leadership of device development programs.
Philip was previously Head of Device Development at AuroScience Pty Ltd, Melbourne, Australia, a wholly owned subsidiary of Aurobindo Pharma USA Inc, focussing on the development of generic inhaled products for global markets.
Before moving to AuroScience, Philip was a management consultant at EY (Australia), where his work focussed on complex project and portfolio and organisational transformation management. Prior to EY, Philip held business development and engineering roles at Team Consulting Ltd (Cambridge, UK), where he led multi-disciplinary teams developing a range of healthcare and drug delivery products. He has also worked at D+I, a leading industrial design consultancy in Australia, as well as The Automation Partnership (now Sartorius Stedim TAP).
Philip joins CHI as they develop and commercialise their αeolus dry powder inhaler (DPI) platform in collaboration with the leading global contract development and manufacturing organisation Kindeva Drug Delivery L.P. The αeolus technology platform is designed to promote greater delivery efficiency and consistency that is independent of patient effort, and to address many of the issues facing existing inhalation technology. It promises to bring new therapies, including those out of reach of existing inhaler technology, to the market more quickly and at lower risk, and to improve the treatment of patients globally.
David Harris, co-founder and CTO, commented:
“We are excited to welcome Philip as the CEO of CHI. Philip brings expertise in leading device development programmes from the proof-of-science stage, and his management, commercial and organisational behaviour and change experience are ideal for CHI as we grow. Coupled with his leadership, Philip’s mechanical engineering and dry powder inhaler expertise continues to bolster our technical strength. I look forward to working with Philip as we develop our novel dry powder inhaler technology, αeolus, and as we continue to innovate into the future to improve patients’ lives.”
Philip Canner, CEO, commented:
“I am delighted to have accepted the role of CEO of CHI at this exciting time in its journey. I look forward to working with the team to develop and commercialise αeolus, and to build and drive the company to meet its strategic objectives. Having worked on several DPI technologies, I can see that the αeolus technology is a truly novel and exciting DPI platform. I look forward to helping CHI succeed with αeolus and all its future innovative technologies that the incredible team will deliver.”
About Cambridge Healthcare Innovations
Cambridge Healthcare Innovations Ltd. is focused on improving the wellbeing and quality of life of patients through the development and implementation of innovative technologies. Founded in August 2018, CHI has patented two technologies to improve the delivery of respiratory medicine – “q‑technology” and “αeolus”.